Cargando…
Rituximab rescue therapy for autoimmune pulmonary alveolar proteinosis
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease characterised by abnormal alveolar surfactant accumulation due to macrophage dysfunction. Whole lung lavage (WLL) is the cornerstone of first-line aPAP therapy, but effective rescue treatments have not yet been well established....
Autores principales: | Bird, Daniel, Evans, Jack, Pahoff, Carl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943437/ https://www.ncbi.nlm.nih.gov/pubmed/35342706 http://dx.doi.org/10.1016/j.rmcr.2022.101637 |
Ejemplares similares
-
Autoimmune pulmonary alveolar proteinosis in a patient with sarcoidosis
por: Tanaka, Yuko, et al.
Publicado: (2019) -
Autoimmune pulmonary alveolar proteinosis prior to myelodysplastic syndrome
por: Foo, Chuan Tai, et al.
Publicado: (2020) -
Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis
por: Malur, Anagha, et al.
Publicado: (2012) -
Autoimmune pulmonary alveolar proteinosis mimicking Mycoplasma pneumonia in an adolescent
por: Meka, Shaiva Ginoya, et al.
Publicado: (2020) -
Pulmonary Alveolar Proteinosis Refractory to Plasmapheresis and Rituximab despite GM-CSF Antibody Reduction
por: Keske, Aysenur, et al.
Publicado: (2022)